| ______________________________________________________________________________________________ 2005-12 All rights Reserved Biolaxy |
| Biolaxy in Operation |
 | |  | |  | |  | |  | |  | |  |
| Leader in Oral Delivery of Biopharmaceuticals |
| Shanghai, August 20, 2005 /For Immediate Release/ -- Shanghai Biolaxy Medical Science & Technology, Inc. today announced that it has completed government registration process and is officially in operation. Biolaxy is registered in Zhangjiang Hi-Park in Shanghai, a premier biotech hub in China. Biolaxy is a wholly owned subsidiary of NOD Pharmaceuticals (www.nodpharm.com), an innovative biotechnology company based in San Diego, California. Biolaxy is developing oral insulin and oral interferon, based on the nano-particle oral delivery or NOD technology developed by NOD Pharmaceuticals. "China offers advantages such as low cost and short development cycle, so we expect to prove our technology and launch our products at a fraction of cost and time of what you might expect otherwise for the US market," William Lee, President & CEO of Biolaxy, explains. NOD technology is a proprietary platform technology that may be used to delivery many biopharmaceutical products in a variety of dosage forms. SOURCE Shanghai Biolaxy, Inc. William Lee, Ph.D, CEO, Shanghai Biolaxy, Inc. 021-5132-0478 URL http://www.biolaxy.com Email info@biolaxy.com |